# What FDA's 2026 evaluation categories mean for GHK-Cu

- Article ID: research-124
- Product: GHK-Cu (ghk-cu-564)
- Canonical page: https://heritagebiolabs.com/research-library/articles/124-what-fda-s-2026-evaluation-categories-mean-for-ghk-cu
- Product collection: https://heritagebiolabs.com/research-library/products/ghk-cu
- Product page: https://heritagebiolabs.com/product/ghk-cu-564
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains connected by peptide bonds. Some, including the three-amino-acid peptide in GHK-Cu, can bind metal ions. GHK-Cu denotes its copper complex. The FDA's May 2026 update on nominated compounding substances addresses how the agency categorized certain forms of the substance for evaluation. That categorization concerns a regulatory process and is separate from evidence of a clinical effect. [1] [2]

The FDA document records a change after a nominator clarified the scope of its submission. The agency returned GHK-Cu to Category 1 for non-injectable forms. Category 1 in this document describes nominated bulk substances under evaluation. The FDA separately identifies concerns about compounded injectable GHK-Cu, including uncertainty about the safety evidence in humans and the potential relevance of impurities or immune reactions. These are two distinct entries with different scopes. [1] [2]

An entry for evaluation says that the agency is considering a nominated bulk substance. FDA approval of a finished drug would involve review of a particular product for a particular indication. A cosmetic study can provide information about appearance or skin measurements. Its conclusions are limited to the tested product and outcomes and do not answer the separate regulatory question. [1] [2]

The May document is a dated account of the agency's evaluation categories. It records the scope of the nomination as it stood at that point. It helps a reader distinguish a nomination from an approved indication and shows why the scope of a regulatory entry matters. Describing one form as under evaluation does not establish the safety or effectiveness of other products that carry the same name. [1] [2]

## Sources

1. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Food and Drug Administration (publication 2026-05-14). <https://www.fda.gov/media/94155/download>
2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration (publication 2026). <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 025 - Fragment 176-191 and GHK-Cu.docx; article 124; content SHA-256 b4e38ae33ce18a0e6112ac54061071e634c6373d908f3c075fb169a4faa2f033.
